H2AFJ has oncogenic functions and is highly expressed in glioblastoma multiforme (GBM), particularly in mesenchymal GBM, where patients show poor response to temozolomide chemotherapy and have a worse prognosis [32]. This evidence concerns the gene H2AJ and glioblastoma.